- Titel
- Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate
- Untertitel
- A Combined Retrospective and Prospective Analysis
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-706271
- Quellenangabe
- Urologia Internationalis Erscheinungsort: Basel
Verlag: Karger
Erscheinungsjahr: 2018
Jahrgang: 100
Heft: 1
Seiten: 72-78
ISSN: 0042-1138
E-ISSN: 1423-0399 - Erstveröffentlichung
- 2018
- Abstract (EN)
- Introduction: We investigated the health-related quality of life (HRQoL) of long-term prostate cancer patients who received leuprorelin acetate in microcapsules (LAM) for androgen-deprivation therapy (ADT). Methods: The observational study was carried out by 30 office-based German urologists in 536 prostate cancer (PCa) patients treated for ≥5 years with LAM and in 116 patients of an age-matched control group (CG). Data on HRQoL and health status was collected prospectively using validated questionnaires QLQ-C30, QLQ-PR25 and Karnofsky Index. Data on effectiveness (clinical response, prostate specific antigen [PSA], testosterone) and safety was collected retrospectively from patients’ health records. We used descriptive statistics to analyze the data. Results: The mean treatment duration was 8.6 years (range 4.5–19.8 years). General health status (QLQ-C30) was comparable for both groups. Differences were observed regarding physical – and role functioning. ADT patients rated single items slightly worse than CG. Karnofsky-Index showed comparable high values (median of 90%). QLQ-PR25 revealed more PCa-related symptoms for ADT patients. Within 6 months, median PSA level declined >90% and median testosterone levels declined below castration level from 4.0 to 0.2 ng/mL. Clinical response (European Organisation for Research and Treatment of Cancer criteria) was observed in at least 90% of ADT patients. Conclusions: Long-term ADT with LAM is a well-accepted, tolerated, effective, and low-burden treatment option for patients with advanced, hormone-sensitive PCa.
- Andere Ausgabe
- Link zum Artikel der zuerst in der Zeitschrift 'Urologia Internationalis' erschienen ist
DOI: 10.1159/000479434 - Freie Schlagwörter (DE)
- Prostatakrebs, Androgen-Entzugstherapie, Leuprorelin-Acetat, Gesundheitsbezogene Lebensqualität
- Freie Schlagwörter (EN)
- Prostate cancer, Androgen-deprivation therapy, Leuprorelin acetate, Health-related quality of life
- Klassifikation (DDC)
- 610
- Verlag
- Karger, Basel
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-706271
- Veröffentlichungsdatum Qucosa
- 22.05.2020
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
